New Systemic Therapies in Hepatocellular Carcinoma

Program Overview

For over a decade, sorafenib was the only systemic agent available for the treatment of advanced hepatocellular carcinoma (HCC). However, the past 2.5 years has added 6 additional agents. In this Clinical ForumSM, our multidisciplinary expert roundtable convenes to discuss their collaborative care strategies for first and subsequent line management of advanced HCC using case-based scenarios.

Credit Expired
CE Credit Expired
Expires: December 19, 2020

Target Audience

This activity is designed to meet the educational needs of oncology providers, including physicians, nurse practitioners, and physician assistants who manage patients with hepatocellular carcinoma (HCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Appropriately utilize multi-targeted tyrosine kinase inhibitors for the management of advanced hepatocellular carcinoma (HCC) based on clinical evidence for their use
  • Incorporate immune checkpoint inhibitors in the management of advanced HCC based on their efficacy and safety data
  • Select appropriate therapy for patients with advanced HCC across multiple lines of therapy

Activity Faculty


Ghassan K. Abou-Alfa, MD, MBA (Chair)

Memorial Sloan Kettering Cancer Center
New York, NY


Anne M. Covey, MD

Memorial Hospital for Cancer and Allied Diseases
New York, NY


Amit Singal, MD, MS

David Bruton Jr. Professor, Clinical Cancer Research
Associate Professor, Medicine
Medical Director, Liver Tumor Program
Clinical Chief, Hepatology
University of Texas Southwestern
Dallas, TX

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

© Copyright 2023. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources